QLS1410
Phase 1Small molecule
Qilu Pharmaceutical Co., Ltd.QLS1410 is one of 60 small molecule programs targeting Essential Hypertension. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
120 competitors in Adult
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
Skyclarys
BiogenPhase 1
Sunlenca
GileadPhase 1
Briviact
UCBPhase 1
NM8074
NNovelMed Therapeutics
Phase 2
Lanoxin
AAdvanz Pharma
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QLS1410. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details